

Vermont's Pharmaceutical Marketer Price Disclosure

In accordance with the Vermont Pharmaceutical Marketer Price Disclosure Law (18 V.S.A. Section 4633), Astellas is disclosing certain required pricing information to individuals authorized to prescribe prescription drugs that Astellas markets in pill form that are not distributed in unit dose packages in Vermont, as well as disclosing pricing information for other prescription drugs in the same therapeutic class.

Please choose a product from the list, and select either "Long form" or "Short form" below.

ASTAGRAF XL® (tacrolimus) Capsules	Long Form	Short Form
MYRBETRIQ® (mirabegron) Tablets	Long Form	Short Form
PROGRAF® (tacrolimus) Capsules	Long Form	Short Form
VESICARE® (solifenacin) Tablets	Long Form	Short Form
XTANDI® (enzalutamide)	Long Form	Short Form
XOSPATA® (gilteritinib)	Long Form	Short Form
VEOZAH™ (fezolinetant) Tablets	Long Form	Short Form

The listing of Other Products in the disclosure forms is not intended to imply that such Other Products are interchangeable with the marketed product or have the same efficacy or safety. Please refer to each product's FDA-approved prescribing information for such determinations. To access approved prescribing information for Astellas™ products, visit [here](#).

The prescribing information approved by the U.S. Food and Drug Administration (FDA) must continue to guide appropriate use of Astellas™ medicines. The intent of this Web site is only to provide pricing information to individuals licensed to prescribe drugs by the State of Vermont in

accordance with Vermont's law. For more detailed information or healthcare advice, members of the public should consult healthcare professionals.

The Other Products identified on the disclosure forms are the other products listed in the same therapeutic class as the marketed product in the American Hospital Formulary Service ("AHFS") Pharmacologic-Therapeutic Classification system. Vermont requires manufacturers to use the AHFS classification system to determine which products are in the same therapeutic class and should be listed on the disclosure form. The AHFS Pharmacologic-Therapeutic Classification is available on the internet at <http://www.ahfsdruginformation.com/>.

The price per pill disclosed is derived from Average Wholesale Prices (AWP) as established and made available to the public by a third party publisher or as calculated from data made available to the public by a third party publisher. We are required to use these prices for the disclosure forms.